Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03811912 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Tolerability Study of Two Dose Regimens of CTP-543 in Adults With Alopecia Areata
A Phase 2 study, sponsored by Concert Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 57
- Enrollment target
NCT03811912 is a Phase 2 study that has completed, run by Concert Pharmaceuticals. The registered enrollment target is 57 participants.
The verdict
NCT03811912, a Phase 2 study, has completed, sponsored by Concert Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 57 participants
- Enrollment target
Study Summary
This study will evaluate the efficacy and tolerability of once-daily versus twice-daily dosing of CTP-543, in adult patients with chronic, moderate to severe alopecia areata.
Interventions
- DRUG CTP-543
- DRUG CTP-543 Matching Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2019-03-21 |
| Est. Completion | 2019-11-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03811912
The ClinicalTrials.gov registry entry for NCT03811912 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Concert Pharmaceuticals, which has 24 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which CTP-543 is the first listed.
NCT03811912 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03811912 about?
NCT03811912 is a clinical study titled "Efficacy and Tolerability Study of Two Dose Regimens of CTP-543 in Adults With Alopecia Areata". This study will evaluate the efficacy and tolerability of once-daily versus twice-daily dosing of CTP-543, in adult patients with chronic, moderate to severe alopecia areata.
What is the current status of trial NCT03811912?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 57 participants. The study started on 2019-03-21. Estimated completion is 2019-11-21.
What interventions are being tested in trial NCT03811912?
The interventions under investigation include: CTP-543 (DRUG), CTP-543 Matching Placebo (DRUG).
Who is sponsoring clinical trial NCT03811912?
This trial is sponsored by Concert Pharmaceuticals, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.